GNR-068 (ustekinumab biosimilar) / Generium - LARVOL DELTA

UKM-PS-III: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=422 | Active, not recruiting | Sponsor: AO GENERIUM | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

UKM-PS-III: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=422 | Active, not recruiting | Sponsor: AO GENERIUM

New P3 trial • Dermatology • Immunology • Psoriasis

A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers (clinicaltrials.gov) - P1 | N=122 | Completed | Sponsor: AO GENERIUM

New P1 trial